Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desoxyrhaponticin is a naturally occurring stilbene glycoside found predominantly in the roots of rhubarb species such as Rheum palmatum and Rheum tanguticum. It is chemically classified as a derivative of rhaponticin and features a glucose moiety attached to a stilbene backbone. Desoxyrhaponticin acts primarily as an inhibitor of fatty acid synthase (FASN), disrupting fatty acid biosynthesis in cells. This inhibition leads to apoptosis in human cancer cells by impairing membrane formation and energy homeostasis. Additionally, it may suppress inflammatory mediators like nitric oxide and pro-inflammatory cytokines in immune cells and has been noted for potential anti-diabetic effects through inhibition of glucose uptake[1][2][5][7]. Desoxyrhaponticin is also present as one component of the herbal extract ERr 731®, which has been studied for alleviating climacteric complaints in perimenopausal women[10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desoxyrhaponticin.